OTC Healthcare in the GCC: Greater Accessibility, Greater Regulatory Responsibility

The over-the-counter (OTC) healthcare market across the Gulf Cooperation Council (GCC) is expanding rapidly. Driven by growing health awareness, rising healthcare costs, digital transformation, and increasing consumer preference for self-care, OTC products have become an integral part of the region's healthcare ecosystem.

From pain relief medications and cold remedies to vitamins, supplements, and wellness products, consumers now have unprecedented access to healthcare solutions without the need for a prescription.

According to recent market estimates, the GCC OTC drugs market was valued at approximately USD 3.7 billion in 2025 and is expected to more than double over the next decade, reaching over USD 7.5 billion by 2034.

This growth is fuelled by increasing urbanization, a younger digitally connected population, expanding pharmacy networks, and the rise of e-commerce healthcare platforms.

Growth Creates Opportunity — and Regulatory Complexity

While greater accessibility creates significant commercial opportunities, it also introduces a growing range of regulatory challenges.

For manufacturers, distributors, and market authorization holders, OTC products are often perceived as lower-risk products from a regulatory perspective. In reality, increased accessibility frequently leads to increased regulatory scrutiny.

As OTC products become more widely available through retail pharmacies, online channels, and direct-to-consumer platforms, GCC regulators are strengthening oversight to ensure product safety, efficacy, quality, and responsible promotion.

Authorities such as the Saudi Food and Drug Authority (SFDA), the Emirates Drug Establishment (EDE), and other GCC regulatory bodies continue to enhance their frameworks to keep pace with evolving market dynamics and consumer behaviour.

Product Classification: One of the Biggest Challenges

One of the most significant regulatory challenges facing companies is product classification.

Products that may be classified as dietary supplements, cosmetics, medical devices, or OTC medicines in one market may fall under a completely different regulatory category in another.

A product successfully marketed as a supplement in one jurisdiction may be classified as a pharmaceutical product elsewhere due to its ingredients, dosage, intended use, or promotional claims.

These classification differences can significantly impact registration requirements, approval timelines, labelling obligations, and post-market responsibilities.

Companies entering multiple GCC markets often discover that a single product may require entirely different regulatory pathways depending on the country and the authority reviewing the submission.

The Rise of Preventive Healthcare and Wellness Products

The challenge becomes even more pronounced as consumer demand shifts toward preventive healthcare and wellness solutions.

The GCC has witnessed substantial growth in vitamins, minerals, herbal products, immunity boosters, and other self-care categories as governments encourage healthier lifestyles and consumers take a more proactive approach to managing their health.

While these products may appear straightforward from a commercial standpoint, they frequently occupy regulatory grey areas that require careful assessment before market entry.

Advertising & Promotion Under the Regulatory Spotlight

Another area of increasing regulatory focus is product promotion and advertising.

The widespread use of social media, influencer marketing, digital advertising, and e-pharmacy platforms has transformed how OTC products reach consumers.

However, increased visibility often translates into greater regulatory exposure.

Claims related to disease prevention, treatment, symptom relief, or therapeutic benefits are closely scrutinized by regulators.

Promotional materials that overstate efficacy, omit important safety information, or imply unapproved indications can trigger regulatory action.

Even minor differences in wording may determine whether a product is viewed as a wellness solution or a medicinal product requiring additional regulatory controls.

The Impact of Digital Healthcare Channels

The growth of digital healthcare channels has further amplified these risks.

Online pharmacies and e-commerce platforms continue to expand throughout the GCC, making healthcare products available to consumers faster than ever before.

While this accessibility improves patient convenience, it also raises expectations around product information accuracy, advertising compliance, traceability, and post-market monitoring.

Post-Market Surveillance Is No Longer Optional

Post-market surveillance is becoming another critical component of OTC compliance strategies.

As products reach larger consumer populations, regulators increasingly expect companies to maintain robust systems for monitoring adverse events, product complaints, safety concerns, and quality issues.

A product's regulatory journey does not end with approval; maintaining compliance throughout its lifecycle is now an essential requirement for long-term market success.

The Strategic Importance of the GCC Market

The importance of these obligations is magnified by the size and strategic significance of the GCC healthcare sector.

Saudi Arabia remains the region's largest pharmaceutical market, accounting for more than half of total pharmaceutical spending in the Gulf.

Together, Saudi Arabia and the UAE represent the majority of pharmaceutical consumption in the region, making regulatory compliance in these markets a key determinant of commercial success.

Building a Lifecycle Regulatory Strategy

For companies operating in the OTC sector, regulatory strategy must extend beyond obtaining initial approvals.

Successful organizations take a lifecycle approach that incorporates product classification, registration planning, labelling compliance, promotional review, post-market surveillance, regulatory intelligence, and ongoing maintenance activities.

This proactive approach reduces the risk of delays, non-compliance findings, market interruptions, and reputational damage.

Conclusion

As OTC healthcare continues its rapid expansion across the GCC, accessibility and regulatory risk are becoming increasingly interconnected.

The products that are easiest for consumers to access are often those that receive the greatest regulatory attention.

Companies that recognize this reality and build strong compliance foundations will be best positioned to capitalize on the region's growing self-care market.

As OTC healthcare continues to evolve, partnering with an experienced regulatory affairs team can help transform compliance from a challenge into a competitive advantage.

Reach out to us to partner:

www.pra-me.com